DIAXONHIT Signs Service Sub-licensing Deal To Process CareDx AlloMap Tests

(RTTNews) - DIAXONHIT, a French firm for specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announced Monday that it entered into a service sub-licensing agreement with the Strasbourg University Hospitals for the performance of the CareDx, Inc. (CDNA) AlloMap test in a dedicated facility as its Central European Laboratory.

Under this agreement, all testing activities will be performed in HUS' Central Immunology Laboratory, under the authority and exclusive responsibility of HUS and its scientific director, Professor Seiamak Bahram.

The AlloMap molecular blood test is a novel method for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. All patients' blood samples collected in heart transplant centers around Europe will be shipped to the Strasbourg facility where the AlloMap testing procedure will be performed. Test results will be sent back directly from the Central Laboratory to the clinicians, consisting primarily of cardiologists and heart surgeons.

DIAXONHIT noted that it is the exclusive European distributor of the AlloMap test. It will supply the central laboratory with specific AlloMap plates and control reagents both manufactured by CareDx, the developer and licensor of AlloMap. DIAXONHIT will also supply heart transplant centers with a kit to facilitate blood samples handling and shipment.

Staff training will be initiated soon by DIAXONHIT and CareDx in order for the laboratory to become operational during the first half of 2015.